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Background
Adult T-cell leukemia/lymphoma (ATL) is a rare and
often fatal outcome of infection with human T-lympho-
tropic virus type I (HTLV-I). Altered host immunity in
HTLV-I carriers has been postulated as a risk factor for
ATL, but is not well understood.
Methods
We prospectively examined well-validated serologic
markers of HTLV-I pathogenesis and host immunity in
53 incident ATL cases and 150 carefully matched
asymptomatic HTLV-I carriers from eight population-
based studies in Japan, Jamaica, the United States and
Brazil. We used multivariable conditional logistic regres-
sion, conditioned on the matching factors (cohort/race,
age, sex, and sample collection year), to evaluate the
biomarkers’ associations with ATL in all subjects and by
years (≤5, >5) from blood draw to ATL diagnosis.
Results
In the pooled population, above-median soluble inter-
leukin-2-receptor-alpha levels (sIL2R, v. ≤ median; odds
ratio (OR), 95% confidence interval (CI)=4.08, 1.47-
11.29) and anti-Tax seropositivity (anti-Tax; OR, 95%
CI=2.97, 1.15-7.67), which indicate T cell activation and
HTLV-I replication, respectively, were independently
associated with an increased ATL risk. Above-median
total immunoglobulin E levels (v. ≤ median; OR, 95%
CI=0.45, 0.19-1.06), which indicate type 2 (B cell) activa-
tion, predicted a lower ATL risk. The sIL2R and anti-
Tax associations with ATL were stronger in samples
collected ≤5 years pre-diagnosis.
Conclusions
The biomarker profile predictive of ATL risk suggests a
role for heightened T cell activation and HTLV-I repli-
cation and diminished type 2 immunity in the etiology
of ATL in HTLV-I carriers. Translation of these findings
to clinical risk prediction or early ATL detection
requires further investigation.
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